Reed-Sternberg Cells and the TNF Family of Receptors/Ligands

References

• Urba W.J., Longo D.L. Hodgkin's disease. N. Engl. J. Med. 1992; 326: 678–687
   PubMed Web of Science ®Google Scholar
• Tesch H., Diehl V. Hodgkin's disease: from basic science to clinical applications. Leukemia 1996; 10: 74–77
   PubMedGoogle Scholar
• Poppema S., Kaleta J., Hepperle B., Visser L. Biology of Hodgkin's disease. Ann. Oncol. 1992; 3: 5–8, (suppl 4)
   PubMedGoogle Scholar
• Johnson D., Lanahan A., Buck C.R., Sehgal A., Morgan C., Mercer E., Bothwell M., Chao M. Expression and structure of the human NGF receptor. Cell 1986; 47: 545–554
   PubMed Web of Science ®Google Scholar
• Smith D.A., Davis T., Anderson D., Solam L., Beckmann M.P., Jerzy R., Dower S.K., Cosman D., Goodwin R.G. A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins. Science 1990; 248: 1019–1023
   PubMed Web of Science ®Google Scholar
• Schall T.J., Lewis M., Koller K.J., Lee A., Rice G.C., Wong G.H., Gananga T., Granger G.A., Lentz R., Raab H., Kohr W.J., Goeddel D.V. Molecular cloning and expression of a receptor for human tumor necrosis factor. Cell 1990; 61: 361–370
   PubMed Web of Science ®Google Scholar
• Loetscher H., Pan Y.C., Lahm H.W., Lesslauer W. Molecular cloning and expression on the human 55 kD tumor necrosis factor receptor. Cell 1990; 61: 351–359
   PubMed Web of Science ®Google Scholar
• Baens M., Chaffanet M., Cassiman J.J., Van den Berghe H., Marynen P. Construction and evaluation of a hncDNA library of human 12p transcribed sequences derived from a somatic cell hybrid. Genomics 1993; 16: 214–218
   PubMed Web of Science ®Google Scholar
• Camerini D., Walz G., Loenen W.A., Borst J., Seed B. The T-cell activation antigen CD27 is a member of the nerve growth factor/tumor necrosis factor receptor gene family. J. Immunol. 1991; 147: 3165–3169
   PubMed Web of Science ®Google Scholar
• Stamenkovic I., Clark E.A., Seed B. A B-lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas. EMBO J 1989; 8: 1403–1410
   PubMed Web of Science ®Google Scholar
• Durkop H., Latza U., Hummel M., Eitelbach F., Seed B., Stein H. Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease. Cell 1992; 68: 421–427
   PubMed Web of Science ®Google Scholar
• Mallett S., Fossum S., Barclay A.N. Characterization of the MRC OX40 antigen of activated CD4 positive T-lymphocytes–a molecule related to nerve growth factor receptor. EMBO J 1990; 9: 1063–1086
   PubMed Web of Science ®Google Scholar
• Kwon B.S., Weissman S.M. cDNA sequences of two inducible T-cell genes. Proc. Natl. Acad. Sci. USA 1989; 86: 1963–1967
   PubMed Web of Science ®Google Scholar
• Itoh N., Yonehara S., Ishii A., Yonehara M., Mizushima S., Sameshima M., Hase A., Seto Y., Nagata S. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 1991; 66: 233–243
   PubMed Web of Science ®Google Scholar
• Oehm A., Behrmann I., Falk W., Pawlita M., Maier G., Klas C., Li-Weber M., Richards S., Dhein J., Trauth B.C. Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. Sequence identity with the Fas antigen. J. Biol. Chem. 1992; 267: 10709–15
   PubMed Web of Science ®Google Scholar
• Berberich I., Shu G., Siebelt F., Woodgett J.R., Kyriakis J.M., Clark E.A. Cross-linking CD40 on B-cells preferentially induces stress-activated protein kinases rather than mitogen-activated protein kinases. EMBO J 1996; 15: 92–101
   PubMed Web of Science ®Google Scholar
• Josimovic-Alasevic O., Durkop H., Schwarting R., Backe E., Stein H., Diamanstein T. Ki-1 (CD30) antigen is released by Ki-1 positive tumor cells in vitro and in vivo Partial characterization of soluble Ki-1 antigen and detection of the antigen in cell culture supernatnants and in serum by and enzyme-linked immunosorbent assay. Eur. J. Immunol. 1989; 19: 157–162
   PubMed Web of Science ®Google Scholar
• Kohno T., Brewer M.T., Baker S.L., Schwartz P.E., King M.W., Hale K.K., Squires C.H., Thompson R.C., Vannice J.L. A second tumor necrosis factor receptor gene product can shed a naturally occurring tumor necrosis factor inhibitor. Proc. Natl. Acad. Sci. U S A 1990; 87: 8331–8335
   PubMed Web of Science ®Google Scholar
• Lantz M., Gullberg U., Nilsson E., Olsson I. Characterization in vitro of a human tumor necrosis factor-binding protein. A soluble form of a tumor necrosis factor receptor. J. Clin. Invest. 1990; 86: 1396–1342
   PubMed Web of Science ®Google Scholar
• Porteu F., Nathan C. Shedding of tumor necrosis factor receptors by activated human neutrophils. J. Exp. Med. 1990; 172: 599–607
   PubMed Web of Science ®Google Scholar
• Hintzen R.Q., De Jong R., Hack C.E., Chamuleau M., De Vries E.F., Ten Berge I.J., Borst J., Van Lier R.A. A soluble form of the human T-cell differentiation antigen CD27 is released after triggering of the TCR/CD3 complex. J. Immunol. 1991; 147: 29–35
   PubMed Web of Science ®Google Scholar
• Loenen W.A., De Vries E., Gravestein L.A., Hintzen R.Q., Van Lier R.A., Borst J. The CD27 membrane receptor, a lymphocyte-specific member of the nerve growth factor receptor family, gives rise to a soluble form by protein processing that does not involve receptor endocytosis. Eur. J. Immunol. 1992; 22: 447–455
   PubMed Web of Science ®Google Scholar
• Van Kooten C., Gaillard C., Galizzi J.P., Hermann P., Fossiez F., Banchereau J., Blanchard D. B-cells regulate expression of CD40 ligand on activated T-cells by lowering the mRNA level and through the release of soluble CD40. Eur. J. Immunol. 1994; 24: 787–792
   PubMed Web of Science ®Google Scholar
• Cheng J., Zhou T., Liu C., Shapiro J.P., Brauer M.J., Kiefer M.C., Barr P.J., Mountz J.D. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 1994; 263: 1759–1762
   PubMed Web of Science ®Google Scholar
• Falini B., Piled S., Pizzolo G., Durkop H., Flenghi L., Stirpe F., Martelli M.F., Stein H. CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood 1995; 85: 1–14
   PubMed Web of Science ®Google Scholar
• Younes A., Consoli U., Snell V., Kliche K.O., Thomas E., Armitage R., Cabanillas F., Andreeff M. Soluble CD30 decreased the availability of CD30 ligand (CD30L) on peripheral blood lymphocytes in patients with CD30+ tumors: a mechanism for evading immunosurveillance. Ann. Oncol. 1995; 7: 149, (abstr)
   Google Scholar
• Owen-Schaub L.B., Angelo L.S., Radinsky R., Ware C.F., Gesner T.G., Bartos D.P. Soluble Fas/APO-1 in tumor cells: a potential regulator of apoptosis. Cancer 1995; 94: 1–8
   Web of Science ®Google Scholar
• Bradshaw R.A., Blundell T.L., Lapatto R., McDonald N.Q., Murray-Rust J. Nerve growth factor revisited. Trends. Biochem. Sci. 1993; 18: 48–52
   PubMedGoogle Scholar
• Eide F.F., Lowenstein D.H., Reichardt L.F. Neurotrophins and their receptors-current concepts and implications for neurologic disease. Exp. Neurol. 1993; 121: 200–214
   PubMed Web of Science ®Google Scholar
• Pennica D., Nedwin G.E., Hayflick J.S., Seeburg P.H., Derynck R., Palladino M.A., Kohr W.J., Aggarwal B.B., Goeddel D.V. Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin. Nature 1984; 312: 724–729
   PubMed Web of Science ®Google Scholar
• Old L.J. Tumor necrosis factor (TNF). Science 1985; 230: 630–632
   PubMed Web of Science ®Google Scholar
• Beutler B., Cerami A. Cachectin and tumour necrosis factor as two sides of the same biological coin. Nature 1986; 320: 584–588
   PubMed Web of Science ®Google Scholar
• Gray P.W., Aggarwal B.B., Benton C.V., Bringman T.S., Henzel W.J., Jarrett J.A., Leung D.W., Moffat B., Ng P., Svedersky L.P. Cloning and expression of cDNA for human lymphotoxin, a lymphokine with tumour necrosis activity. Nature 1984; 312: 721–724
   PubMed Web of Science ®Google Scholar
• Aggarwal B.B., Henzel W.J., Moffat B., Kohr W.J., Harkins R.N. Primary structure of human lymphotoxin derived from 1788 lymphoblastoid cell line. J. Biol. Chem. 1985; 260: 2334–2344
   PubMed Web of Science ®Google Scholar
• Browning J.L., Ngam-Ek A., Lawton P., De Marinis J., Tizard R., Chow E.P., Hession C., O'Brine-Greco B., Foley S.F., Ware C.F. Lymphotoxin beta, a novel member of the TNF family that forms a heteromeric complex with lymphotoxin on the cell surface. Cell 1993; 72: 847–856
   PubMed Web of Science ®Google Scholar
• Goodwin R.G., Alderson M.R., Smith C.A., Armitage R.J., Vanden Bos T., Jerzy R., Tough T.W., Schoenborn M.A., Davis-Smith T., Hennen K. Molecular and biological characterization of a ligand for CD27 defines a new family of cytokines with homology to tumor necrosis factor. Cell 1993; 73: 447–456
   PubMed Web of Science ®Google Scholar
• Smith C.A., Grass H.J., Davis T., Anderson D., Farrah T., Baker E., Sutherland G.R., Brannan C.I., Copeland N.G., Jenkins N.A. CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF. Cell 1993; 73: 1349–1360
   PubMed Web of Science ®Google Scholar
• Armitage R.J., Fanslow W.C., Strockbine L., Sato T.A., Clifford K.N., Macduff B.M., Anderson D.M., Gimpel S.D., Davis-Smith T., Maliszewski C.R. Molecular and biological characterization of a murine ligand for CD40. Nature 1992; 357: 80–82
   PubMed Web of Science ®Google Scholar
• Graf D., Korthauer U., Mages H.W., Senger G., Kroczek R.A. Cloning of TRAP, a ligand for CD40 on human T-cells. Eur. J. Immunol. 1992; 22: 3191–3194
   PubMed Web of Science ®Google Scholar
• Francis D.A., Karras J.G., Ke X.Y., Sen R., Rothstein T.L. Induction of the transcription factors NF-kappa B, AP-1 and NF-AT during B-cell stimulation through the CD40 receptor. Int. Immunol 1995; 7: 151–161
   PubMed Web of Science ®Google Scholar
• Saiki O., Tanaka T., Wada Y., Uda H., Inoue A., Katada Y., Izeki M., Iwata M., Nunoi H., Matsuda I. Signaling through CD40 rescues IgE but not IgG or IgA secretion in X-linked immunodeficiency with hyper-IgM. J. Clin. Invest. 1995; 95: 510–514
   PubMed Web of Science ®Google Scholar
• Gauchat J.F., Aubry J.P., Mazzei G., Life P., Jomotte T., Elson G., Botmefoy J.Y. Human CD40-ligand: molecular cloning, cellular distribution and regulation of expression by factors controlling IgE production. FEBS Lett 1993; 315: 259–266
   PubMed Web of Science ®Google Scholar
• Goodwin R.G., Din W.S., Davis-Smith T., Anderson D.M., Gimpel S.D., Sato T.A., Maliszewski C.R., Brannan C.I., Copeland N.G., Jenkins N.A. Molecular cloning of a ligand for the inducible T-cell gene 4–1BB: a member of an emerging family of cytokines with homology to tumor necrosis factor. Eur. J. Immunol. 1993; 23: 2631–2641
   PubMed Web of Science ®Google Scholar
• Alderson M.R., Smith C.A., Tough T.W., Davis-Smith T., Armitage R.J., Falk B., Roux E., Baker E., Sutherland G.R., Din W.S. Molecular and biological characterization of human 4-IBB and its ligand. Eur. J. Immunol. 1994; 24: 2219–2227
   PubMed Web of Science ®Google Scholar
• Ziegler S.F., Bird T.A., Schneringer J.A., Schooley K.A., Baum P.R. Molecular cloning and characterization of a novel receptor protein tyrosine kinase from human placenta. Oncogene 1993; 8: 663–670
   PubMed Web of Science ®Google Scholar
• Godfrey W.R., Fagnoni F.F., Harara M.A., Buck D., Engleman E.G. Identification of a human OX-40 ligand, a costimulator of CD4+ T-cells with homology to tumor necrosis factor. J. Exp. Med. 1994; 180: 757–762
   PubMed Web of Science ®Google Scholar
• Suda T., Takahashi T., Golstein P., Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993; 75: 1169–1178
   PubMed Web of Science ®Google Scholar
• Alderson M.R., Tough T.W., Davis-Smith T., Braddy S., Falk B., Schooley K.A., Goodwin R.G., Smith C.A., Ramsdell F., Lynch D.H. Fas ligand mediates activation-induced cell death in human T-lymphocytes. J. Exp. Med. 1995; 181: 71–77
   PubMed Web of Science ®Google Scholar
• Lynch D.H., Watson M.L., Alderson M.R., Baum P.R., Miller R.E., Tough T., Gibson M., Davis-Smith T., Smith C.A., Hunter K. The mouse Fasligand gene is mutated in gld mice and is part of a TNF family gene cluster. Immunity 1994; 1: 131–136
   PubMed Web of Science ®Google Scholar
• Takahashi T., Tanaka M., Brannan C.I., Jenkins N.A., Copeland N.G., Suda T., Nagata S. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell 1994; 76: 969–976
   PubMed Web of Science ®Google Scholar
• Wiley S.R., Schooley K., Smolak P.J., Din W.S., Huang C.-P., Nicholl J.K., Sutherland G.R., Smith T.D., Rauch C., Smith C.A., Goodwin R.G. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995; 3: 673–682
   PubMed Web of Science ®Google Scholar
• Gruss H.J., Dower S.K. Tumor necrosis factor ligand superfamily: involvement in the pathology of malignant lymphomas. Blood 1995; 85: 3378–3404
   PubMed Web of Science ®Google Scholar
• Baum P.R., Gayle R.B., Ramsdell F., Srinivasan S., Sorensen R.A., Watson M.L., Seldin M.F., Clifford K.N., Grabstein K., Alderson M.R. Identification of OX40 ligand and preliminary characterization of its activities on OX40 receptor. Circ. Shock 1994; 44: 30–34
   PubMedGoogle Scholar
• Armitage R.J., Tough T.W., Macduff B.M., Fanslow W.C., Spriggs M.K., Ramsdell F., Alderson M.R. CD40 ligand is a T-cell growth factor. Eur. J. Immunol. 1993; 23: 2326–2331
   PubMed Web of Science ®Google Scholar
• Bazzoni F., Beutler B. Seminars in medicine of the Beth Israel Hospital, Boston: The tumor necrosis factor ligand and receptor families. N. Engl. J. Med., 334: 1717–1725
   PubMedGoogle Scholar
• Younes A., Consoli U., Zhao S., Snell V., Thomas E., Grass H.J., Cabanillas F., Andreeff M. CD30 ligand is expressed on resting normal and malignant human B lymphocytes. Br. J. Haematol. 1996; 93: 569–571
   PubMed Web of Science ®Google Scholar
• Desai-Mehta A., Lu L., Ramsey-Goldman R., Datta S.K. Hyperexpression of CD40 ligand by B- and T-cells in human lupus and its role in pathogenic autoantibody production. J. Clin. Invest. 1996; 97: 2063–2073
   PubMed Web of Science ®Google Scholar
• Gauchat J.F., Henchoz S., Fattah D., Mazzei G., Aubry J.P., Jomotte T., Dash L., Page K., Solari R., Aldebert D. CD40 ligand is functionally expressed on human eosinophils. Eur. J. Immunol. 1995; 25: 863–865
   PubMed Web of Science ®Google Scholar
• Grammer A.C., Bergman M.C., Miura Y., Fujita K., Davis L.S., Lipsky P.E. The CD40 ligand expressed by human B-cells costimulates B-cell responses. J. Immunol. 1995; 154: 4996–5010
   PubMed Web of Science ®Google Scholar
• Griffith T.S., Brunner T., Fletcher S.M., Greend D.R., Ferguson T.A. Fas ligand-induced apoptosis as a mechanism of immune privilege [see comments]. Science 1995; 270: 1189–1192
   PubMed Web of Science ®Google Scholar
• Bellgrau D., Gold D., Selawry H., Moore J., Franzusoff A., Duke R.C. A role for CD95 ligand in preventing graft rejection (see comments). Nature 1995; 377: 630–632
   PubMed Web of Science ®Google Scholar
• Tanaka M., Suda T., Haze K., Nakamura N., Sato K., Kimura F., Motoyoshi K., Mizuki M., Tagawa S., Ohga S., Hatake K., Drummond A.H., Nagata S. Fas ligand in human serum. Nat Med 1996; 2: 317–322
   PubMed Web of Science ®Google Scholar
• Banner D.W., D'Arcy A., Janes W., Gentz R., Schoenfeld H.-J., Broger C., Loetscher H., Lesslauer W. Crystal structure of the soluble human 55 kc TNF receptor-human TNF beta complex: Implications for TNF receptor activation. Cell 1993; 73: 431–445
   PubMed Web of Science ®Google Scholar
• Rothe M., Wong W.C., Henzel W.J., Goeddel D.V. A novel family of putative signal transducers associated with the cytoplasmic domain of the 75 kDa tumor necrosis factor receptor. Cell 1995; 78: 681–692
   Web of Science ®Google Scholar
• Rothe M., Sarma V., Dixit V.M., Goeddel D.V. TRAF2-mediated activation of NF-kappa B by TNF receptor 2 and CD40. Science 1995; 269: 1424–1427
   PubMed Web of Science ®Google Scholar
• Hu H.M., O'Rourke K., Boguski M.S., Dixit V.M. A novel RING finger protein interacts with the cytoplasmic domain of CD40. J. Biol. Chem. 1994; 269: 30069–30072
   PubMed Web of Science ®Google Scholar
• Cheng G., Baltimore D. TANK, a co-inducer with TRAF2 of TNF- and CD 40L-mediated NF-kappaB activation. Genes. Dev. 1996; 10: 963–973
   PubMed Web of Science ®Google Scholar
• Smith C.A., Farrah T., Goodwin R.G. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell 1994; 76: 959–962
   PubMed Web of Science ®Google Scholar
• Chinnaiyan A.M., O'Rourke K., Tewari M., Diwit V.M. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell 1995; 81: 505–512
   PubMed Web of Science ®Google Scholar
• Hsu H., Xiong J., Goeddel D.V. The TNF receptor 1-associated protein TRADD singals cell death and NF-kB activation. Cell 1995; 81: 495–504
   PubMed Web of Science ®Google Scholar
• Heller R.A., Kronke M. Tumor necrosis factor receptor-mediated signaling pathways. J. Cell. Biol. 1994; 125: 5–9
   Web of Science ®Google Scholar
• Rao P., Hsu K.C., Chao M.V. Upregulation of NF-kappa B-dependent gene expression mediated by the p75 tumor necrosis factor receptor. J. Interferon Cytokine Res. 1995; 15: 171–177
   PubMed Web of Science ®Google Scholar
• Gruss H.J., Ulrich D., Dower S.K., Herrmann F., Brach M.A. Activation of Hodgkin cells via the CD30 receptor induces autocrine secretion of interleukin-6 engaging the NF-κB transcription factor. Blood 1996; 87: 2443–2449
   PubMed Web of Science ®Google Scholar
• McDonald P.P., Cassatella M.A., Bald A., Maggi E., Romagnani S., Grass H.J., Pizzolo G. CD30 ligation induces nuclear factor-kappa B activation in human T-cell lines. Eur J Immunol 1995; 25: 2870–2876
   PubMed Web of Science ®Google Scholar
• Beg A.A., Baltimore D. An essential role for NF-kB in preventing cell death. Science 1996; 274: 782–784
   PubMed Web of Science ®Google Scholar
• Wang C.-Y., Mayo M.W., Baldwin A.S., Jr. TNF- and Cancer Therapy-induced apoptosis: Potentiation by inhibition of NF-kB. Science 1996; 274: 784–787
   PubMed Web of Science ®Google Scholar
• Antwerp Van, Martin D. J. S. J., Kafri T., Green D.R., Verma I.M. Suppression on TNF-induced apoptosis by NF-κB. Science 1996; 274: 787–789
   PubMed Web of Science ®Google Scholar
• Gruss H.J., Boiani N., Williams D.E., Armitage R.J., Smith C.A., Goodwin R.G. Pleiotropic effects of the CD30 ligand on CD30-expressing cells and lymphoma cell lines. Blood 1994; 83: 2045–2056
   PubMed Web of Science ®Google Scholar
• Nagata S. Apoptosis regulated by a death factor and its receptor: Fas ligand and Fas. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 1994; 345: 281–287
   PubMed Web of Science ®Google Scholar
• Alderson M.R., Armitage R.J., Maraskovsky E., Tough T.W., Roux E., Schooley K., Ramsdell F., Lynch D.H. Fas transduces activation signals in normal human T-lymphocytes. J. Exp. Med. 1993; 178: 2231–2235
   PubMed Web of Science ®Google Scholar
• Armitage R.J., Maliszewski C.R., Alderson M.R., Grabstein K.H., Spriggs M.K., Fanslow W.C. CD40L: a multi-functional ligand. Semin. Immunol 1993; 5: 401–412
   PubMedGoogle Scholar
• Watanabe-Fukunaga R., Brannan C.I., Copeland N.G., Jenkins N.A., Nagata S. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 1992; 356: 314–317
   PubMed Web of Science ®Google Scholar
• Allen R.C., Armitage R.J., Conley M.E., Rosenblatt H., Jenkins N.A., Copeland N.G., Bedell M.A., Edelhoff S., Disteche C.M., Simoneaux D.K. CD40 ligand gene defects responsible for X-linked hyper-IgM syndrome (see comments). Science 1993; 259: 990–993
   PubMed Web of Science ®Google Scholar
• Korthauer U., Graf D., Mages H.W., Briere F., Padayachee M., Malcolm S., Ugazio A.G., Notarangelo L.D., Levinsky R.J., Kroczek R.A. Defective expression of T-cell CD40 ligand causes X-linked immunodeficiency with hyper-IgM (see comments). Nature 1993; 361: 539–541
   PubMed Web of Science ®Google Scholar
• Aruffo A., Farrington M., Hollenbaugh D., Li X., Milatovich A., Nonoyama S., Bajorath J., Grosmaire L.S., Stenkamp R., Neubauer M. The CD40 ligand, gp39, is defective in activated T-cells from patients with X-linked hyper-IgM syndrome. Cell 1993; 72: 291–300
   PubMed Web of Science ®Google Scholar
• Nadali G., Vinante F., Ambrosetti A., Todeschini G., Veneri D., Zanotti R., Meneghini V., Ricetti M.M., Benedetti F., Vassanelli A. Serum levels of soluble CD30 are elevated in the majority of untreated patients with Hodgkin's disease and correlate with clinical features and prognosis. J. Clin. Oncol. 1994; 12: 793–797
   PubMed Web of Science ®Google Scholar
• Gause A., Pohl C., Tschiersch A., Da Costa L., Jung W., Diehl V., Hasenclever D., Pfreundschuh M. Clinical significance of soluble CD30 antigen in the sera of patients with untreated Hodgkin's disease. Blood 1991; 77: 1983–1988
   PubMed Web of Science ®Google Scholar
• Hummel M., Ziemann K., Lammert H., Pileri S., Sabattini E., Stein H. Hodgkin's disease with monoclonal and polyclonal populations of Reed-Sternberg cells. N. Engl. J. Med. 1995; 333: 901–906
   PubMed Web of Science ®Google Scholar
• Davis T.H., Morton C.C., Miller-Cassman R., Balk S.P., Kadin M.E. Hodgkin's disease, lymphomatoid papulosis, and cutaneous T-cell lymphoma derived from a common T-cell clone. N. Engl. J. Med. 1992; 326: 1115–1122
   PubMed Web of Science ®Google Scholar
• Munro J.M., Freedman A.S., Aster J.C., Gribben J.G., Lee N.C., Rhynhart K.K., Banchereau J., Nadler L.M. In vivo expression of the B7 costimulatory molecule by subsets of antigen-presenting cells and the malignant cells of Hodgkin's disease. Blood 1994; 83: 793–798
   PubMed Web of Science ®Google Scholar
• Delabie J., Ceuppens J.L., Vandenberghe P., De Boer M., Coorevits L., De Wolf-Peeters C. The B7/BB1 antigen is expressed by Reed-Sternberg cells of Hodgkin's disease and contributes to the stimulating capacity of Hodgkin's disease-derived cell lines. Blood 1993; 82: 2845–2852
   PubMed Web of Science ®Google Scholar
• Hsu S.M., Hsu P.L. Lymphocyte functional antigens stabilize agglutination between Reed-Sternberg cells and T-cells, but are not responsible for homotypic binding of Hodgkin's Reed-Sternberg cells. Am. J. Pathol. 1990; 137: 563–574
   PubMed Web of Science ®Google Scholar
• Brousset P., Benharroch D., Krajewski S., Laurent G., Meggetto F., Rigal-Huguet F., Gopas J., Prinsloo I., Pris J., Delsol G., Reed J.C., Schlaifer D. Frequent expression of the cell death-inducing gene Bax in Reed-Sternberg cells of Hodgkin's disease. Blood 1996; 78: 2470–2475
   Google Scholar
• Schwab U., Stein H., Gerdes J., Lemke H., Kirchner H.H., Schaadt M., Diehl V. Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin's disease and a subset of normal lymphoid cells. Nature 1982; 299: 65–67
   PubMed Web of Science ®Google Scholar
• Stein H., Gerdes J., Schwab U., Lemke H., Mason D.Y., Ziegler A., Schienle W., Diehl V. Identification of Hodgkin's and Sternberg-Reed cells as a unique cell type derived from a newly-detected small cell population. Int. J. Cancer 1982; 30: 445–459
   PubMed Web of Science ®Google Scholar
• Haluska F.G., Brufsky A.M., Canellos G.P. The cellular biology of the Reed-Sternberg cell. Blood 1994; 84: 1005–1019
   PubMed Web of Science ®Google Scholar
• Gruss H.J., Brach M.A., Drexler H.G., Bonifer R., Mertelsmann R.H., Herrmann F. Expression of cytokine genes, cytokine receptor genes, and transcription factors in cultured Hodgkin and Reed-Sternberg cells. Cancer Res. 1992; 52: 3353–3360
   PubMed Web of Science ®Google Scholar
• Kurzrock R., Redman J., Cabanillas F., Jones D., Rothberg J., Talpaz M. Serum interleukin 6 levels are elevated in lymphoma patients and correlate with survival in advanced Hodgkin's disease and with B symptoms. Cancer Res. 1993; 53: 2118–2122
   PubMed Web of Science ®Google Scholar
• Stein H., Mason D.Y., Gerdes J., O'Connor N., Wainscoat J., Pallesen G., Gatter K., Falini B., Delsol G., Lemke H. The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 1985; 66: 848–858
   PubMed Web of Science ®Google Scholar
• Andreesen R., Osterholz J., Lohr G.W., Bross K.J. A Hodgkin cell-specific antigen is expressed on a subset of auto- and alloactivated T (helper) lymphoblasts. Blood 1984; 63: 1299–1302
   PubMed Web of Science ®Google Scholar
• Gruss H.J., Pinto A., Gloghini A., Wehnes E., Wright B., Boiani N., Aldinucci D., Gattei V., Zagonel V., Smith C.A., Kadin M.E., Shilling C., Goodwin R.G., Herrmann F., Carbone A. CD30 ligand expression in nonmalig-nant and Hodgkin's disease-involved lymphoid tissues. Am. J. Pathol. 1996; 149: 469–481
   PubMed Web of Science ®Google Scholar
• Ellis T.M., Simms P.E., Slivnick D.J., Jack H.M., Fisher R.I. CD30 is a signal-transducing molecule that defines a subset of human activated CD45RO+ T-cells. J. Immunol. 1993; 151: 2380–2389
   PubMed Web of Science ®Google Scholar
• Cambiaggi A., Cantoni C., Marciano S., De Totero D., Pileri S., Tazzari P.L., Stein H., Ferrini S. Cultured human NK cells express the Ki-1/CD30 antigen. Br. J. Haematol. 1993; 85: 270–276
   PubMed Web of Science ®Google Scholar
• Nawrocki J.F., Kirsten E.S., Fisher R.I. Biochemical and structural properties of a Hodgkin's disease related membrane protein. J. Immunol. 1988; 141: 672–680
   PubMed Web of Science ®Google Scholar
• Fonatsch C., Latza U., Durkop H., Rieder H., Stein H. Assignment of the human CD30 (Ki-1) gene to 1p36. Genomics 1992; 14: 825–826
   PubMed Web of Science ®Google Scholar
• Gruss H.J., Da Silva N., Hu Z.B., Uphoff C.C., Goodwin R.G., Drexler H.G. Expression and regulation of CD30 ligand and CD30 in human leukemia-lymphoma cell lines. Leukemia 1994; 8: 2083–2094
   PubMed Web of Science ®Google Scholar
• Pizzolo G., Vinante F., Chilosi M., Dallenbach F., Josimovic-Alasevic O., Diamantstein T. Serum levels of soluble CD30 molecule (Ki-1 antigen) in Hodgkin's disease: relationship with disease activity and clinical stage. Br. J. Haematol. 1990; 75: 282–284
   PubMed Web of Science ®Google Scholar
• Jumper M.D., Nishioka Y., Davis L.S., Lipsky P.E., Meek K. Regulation of human B-cell function by recombinant CD40 ligand and other TNF-related ligands. J. Immunol. 1995; 155: 2369–2378
   PubMed Web of Science ®Google Scholar
• Bowen M.A., Olsen K.J., Cheng L., Avila D., Podack E.R. Functional effects of CD30 on a large granular lymphoma cell line, YT. Inhibition of cytotoxicity, regulation of CD28 and IL-2R, and induction of homotypic aggregation. J. Immunol. 1993; 151: 5896–5906
   PubMed Web of Science ®Google Scholar
• Amakawa R., Hakem A., Kundig T.M., Matsuyama T., Simard J.J., Timms E., Wakeham A., Mittruecker H.W., Griesser H., Takimoto H., Schmits R., Shahinian A., Ohashi P., Penninger J.M., Mak T.W. Impaired negative selection of T-cells in Hodgkin's disease antigen CD30-deficient mice. Cell 1996; 84: 551–562
   PubMed Web of Science ®Google Scholar
• Gruss H.J., Scheffrahn I., Huebinger G., Duyster J., Herrmann F. The CD30 ligand and CD40 ligand regulate CD54 surface expression and release of its soluble form by cultured Hodgkin and Reed-Sternberg cells. Leukemia 1996; 10: 829–835
   PubMed Web of Science ®Google Scholar
• Gruss H.J., Ulrich D., Braddy S., Armitage R.J., Dower S.K. Recombinant CD30 ligand and CD40 ligand share common biological activities on Hodgkin and Reed-Sternberg cells. Eur. J. Immunol. 1995; 25: 2083–2089
   PubMed Web of Science ®Google Scholar
• Del Prete G., De Carli M., Almerigogna F., Daniel C.K., D'Elios M.M., Zancuoghi G., Vinante F., Pizzolo G., Romagnani S. Preferential expression of CD30 by human CD4+ T-cells producing Th2-type cytokines. FASEB J. 1995; 9: 81–86
   PubMed Web of Science ®Google Scholar
• Pizzolo G., Romagnani S. CD30 molecule (Ki-1 Ag): more than just a marker of CD30+ lymphoma. Haematologica 1995; 80: 357–366
   PubMed Web of Science ®Google Scholar
• Del Prete G., Maggi E., Pizzolo G., Romagnani S. CD30, Th2 cytokines and HIV infection: a complex and fascinating link. Immunol Today 1995; 16: 76–80
   PubMedGoogle Scholar
• Gruss H.J., Hirschstein D., Wright B., Ulrich D., Caligiuri M.A., Barcos M., Strockbine L., Armitage R.J., Dower S.K. Expression and function of CD40 on Hodgkin and Reed-Sternberg cells and the possible relevance for Hodgkin's disease. Blood 1994; 84: 2305–2314
   PubMed Web of Science ®Google Scholar
• Xerri L., Carbuccia N., Pare P., Hassoun J., Birg F. Frequent expression of FAS/APO-1 in Hodgkin's disease and anaplastic large cell lymphomas. Histopathology 1995; 27: 235–241
   PubMed Web of Science ®Google Scholar
• Owen-Schaub L.B., Meterissian S., Ford R.J. Fas/APO-1 expression and function on malignant cells of hematologic and nonhematologic origin. J. Immunother. 1993; 14: 234–241
   Web of Science ®Google Scholar
• Nagata S., Golstein P. The Fas death factor. Science 1995; 267: 1449–1456
   PubMed Web of Science ®Google Scholar
• Hahn S., Stalder T., Wernli M., Burgin D., Tschopp J., Nagata S., Erb P. Down-modulation of CD4+ T helper type 2 and type 0 cells by T helper type 1 cells via Fas/Fas-ligand interaction. Eur. J. Immunol. 1995; 25: 2679–2685
   PubMed Web of Science ®Google Scholar
• Ramsdell F., Seaman M.S., Miller R.E., Picha K.S., Kennedy M.K., Lynch D.H. Differential ability of Thl and Th2 T-cells to express Fas ligand and to undergo activation-induced cell death. Int. Immunol. 1994; 6: 1545–1553
   PubMed Web of Science ®Google Scholar
• Carbone A., Gloghini A., Gattei V., Aldinucci D., Degan M., De Paoli P., Zagonel V., Pinto A. Expression of functional CD40 antigen on Reed-Sternberg cells and Hodgkin's disease cell lines. Blood 1995; 85: 780–789
   PubMed Web of Science ®Google Scholar
• O'Grady J.T., Stewart S., Lowrey J., Howie S.E., Krajewski A.S. CD40 expression in Hodgkin's disease [see comments]. Am. J. Pathol 1994; 144: 21–26
   PubMed Web of Science ®Google Scholar
• Renner C., Bauer S., Sahin U., Jung W., Van Lier R., Jacobs G., Held G., Pfreundschuh M. Cure of disseminated xenografted human Hodgkin's tumors by bispecific monoclonal antibodies and human T-cells: the role of human T-cell subsets in a preclinical model. Blood 1996; 87: 2930
   PubMed Web of Science ®Google Scholar